This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (69)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Stanley I. Rapoport, MD; Francesca Bosetti, PhD

Arch Gen Psychiatry. 2002;59:592-596.

Background  Lithium and certain anticonvulsants, including carbamazepine and valproic acid, are effective antimanic drugs for treating bipolar disorder, but their mechanisms of action remain uncertain.

Experimental Observations  Feeding rats lithium chloride for 6 weeks, to produce a brain lithium concentration of 0.7mM, reduced arachidonic acid turnover within brain phospholipids by 75%. The effect was highly specific, as turnover rates of docosahexaenoic acid and palmitic acid were unaffected. Arachidonate turnover in rat brain also was reduced by long-term valproic acid administration. Lithium's reduction of arachidonate turnover corresponded to its down-regulating gene expression and enzyme activity of cytosolic phospholipase A₂, an enzyme that selectively liberates arachidonic but not docosahexaenoic acid from phospholipids. Lithium also reduced the brain protein level and activity of cyclooxygenase 2, as well as the brain concentration of prostaglandin E₂, an arachidonate metabolite produced via cyclooxygenase 2.

Conclusions  These results give rise to the hypothesis that lithium and antimanic anticonvulsants act by targeting parts of the "arachidonic acid cascade," which may be functionally hyperactive in mania. Thus, drugs that target enzymes in the cascade, such as cyclooxygenase 2 inhibitors, might be candidate treatments for mania. Also, in view of competition between arachidonic and docosahexaenoic acids in a number of functional processes, docosahexaenoic acid or its precursors would be expected to be therapeutic. Neither of these predictions is evident from other current hypotheses for the antimanic action of lithium and anticonvulsant drugs.

From the Brain Physiology and Metabolism Section, National Institute on Aging, National Institutes of Health, Bethesda, Md.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The emerging role of group VI calcium-independent phospholipase A2 in releasing docosahexaenoic acid from brain phospholipids
Green et al.
J. Lipid Res. 2008;49:939-944.
ABSTRACT | FULL TEXT  

Chronic N-methyl-D-aspartate administration increases the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat
Lee et al.
J. Lipid Res. 2008;49:162-168.
ABSTRACT | FULL TEXT  

Modulation of Lipid Rafts by {Omega}-3 Fatty Acids in Inflammation and Cancer: Implications for Use of Lipids During Nutrition Support
Siddiqui et al.
Nutr Clin Pract 2007;22:74-88.
ABSTRACT | FULL TEXT  

One generation of n-3 polyunsaturated fatty acid deprivation increases depression and aggression test scores in rats
DeMar et al.
J. Lipid Res. 2006;47:172-180.
ABSTRACT | FULL TEXT  

MOLECULAR EFFECTS of lithium
Quiroz et al.
Mol. Interv. 2004;4:259-272.
ABSTRACT | FULL TEXT  

Electroconvulsive Seizures Regulate Gene Expression of Distinct Neurotrophic Signaling Pathways
Altar et al.
J. Neurosci. 2004;24:2667-2677.
ABSTRACT | FULL TEXT